Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioblastoma multiforme (GBM).
https://finance.yahoo.com/news/fda-grants-orphan-drug-designation-114500847.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.